Johnson & Johnson has announced new data from its Alzheimer's disease research program, which will be presented at the upcoming Alzheimer's Association International Conference $(AAIC)$ in Toronto, Canada, from July 27-31, 2025. The company will share insights across 12 abstracts, focusing on the role of tau in brain function during early Alzheimer's disease and the effectiveness of plasma biomarker pTau217 in tracking cognitive decline. Additionally, findings from the Global Neurodegeneration Proteomics Consortium, co-founded with Gates Ventures, will be introduced. These presentations aim to enhance understanding of neurodegenerative diseases and advance the diagnosis and treatment of Alzheimer's disease.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.